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Highlights are  
 the results of sensitivity analysis of meta-analyses of RCTs in the treatment of 
recurrent pregnancy loss showing a significant therapeutic effect when treatment is 
started pre-conception and  
 not previously published data from a follow-up study of IVIg treatment in their next 
pregnancy of patients who miscarried when they participated in our RCT of IVIg in 
their former pregnancy. These data show that IVIg treatment in a previous 
pregnancy seems to increase the chance of live birth 10 fold in these patients with 
an average of 6 previous pregnancy losses.  
 
Abstract 
Intravenous immunoglobulin (IVIg) has a documented clinical effect in many autoimmune 
diseases and has so far been tested in > 10 randomised controlled trials (RCTs) in women 
with recurrent pregnancy loss (RPL). The results of the RCTs have, however, been very 
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divergent. In meta-analyses of all trials, no significant impact on live birth rate has been 
reported. In contrast, in sensitivity analyses, IVIg significantly increased live birth rates 
when initiated prior to conception and it had a borderline significant therapeutic effect in 
women with secondary RPL. Higher dosages of IVIg and serological signs of autoimmunity 
in the treated patients tended to increase the success rate after treatment. A follow-up 
study of patients form our recent RCT also supports a significant therapeutic effect in 
patients who had received IVIg before conception. The lessons learned from the published 
trials and meta-analyses should be incorporated in the design of future RCTs of IVIg in the 
treatment of RPL.      
 
Introduction 
Recurrent pregnancy loss (RPL) has traditionally been defined as three or more 
consecutive pregnancy losses (miscarriages before gestational week 23 and biochemical 
pregnancies). Some societies of reproductive medicine, however, define RPL as two or 
more pregnancy losses (Practice Committee of ASRM, 2013; The ESHRE Guideline 
Group on RPL, 2018). RPL affects 1-5% of all women trying to conceive depending on the 
definition used. Primary RPL refers to a series of pregnancy losses without a previous birth 
whereas secondary RPL refers to a series of pregnancy losses subsequent to a previous 
live birth or stillbirth. In only a minority is the condition associated with parental 
chromosomal abnormalities, uterine malformations, infectious, endocrine or thrombophilic 
disturbances. In some cases can the condition be explained by repeated chromosomal 
abnormalities in the embryos of parents with normal chromosomes. In primary RPL the 
frequency of embryonal chromosomal abnormality has been reported to be about 55 % 
and in secondary RPL about 35 % (Coulam et al., 1996). 
Immunological disturbances are hypothesized to play an important role in RPL since many 
immunological biomarkers can be found with increased prevalence in women with RPL 
and display a negative prognostic impact (Kruse et al., 2002; Hiby et al., 2008; King et al., 
2010; Thangaratinam et al., 2011.) However, the exact pathophysiological mechanisms 
behind RPL still need clarification. 
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Various types of immune-based therapies have been tested in women experiencing RPL 
including intravenous immunoglobulin (IVIg) (Christiansen et al., 1992; The German 
RSA/IVIG group, 1994; Christiansen et al.,1995). IVIg formulations are made by extracting 
the IgG fractions from plasma from normal blood donors and are safe to use because of 
preventive virus screening and inactivation procedures and transmission of infections (e.g., 
HIV, hepatitis) by IVIg transfusion has not been reported for decades (Späth and Kempf, 
2004). 
High dose IVIg (e.g. 0.4g/kg for 5 days) is an established treatment in many 
autoimmune and inflammatory diseases with a large number of proven or suggested 
mechanisms of action. Some implicated mechanisms of action in autoimmune diseases 
are: interaction with Fc-receptors, inhibition of cell adhesion, inhibition of formation of/or 
elimination of immune complexes, interference with antigen presentation, effects on 
cytokines including neutralization of inflammatory cytokines, effects on apoptosis, 
suppression and neutralization of autoantibodies, attenuation of natural killer (NK) cells, 
and expansion of regulatory T lymphocytes (Negi et al., 2007; Clark et al., 2008; 
Baerenwaldt et al., 2010; Schwab and Nimmerjahn, 2013). Suppression of NK cell cytolytic 
activity by IVIg seems to be partially mediated by the CD200 tolerance signaling molecule 
acting on non-NK cells, which then act on NK cells by direct contact (Clark et al., 2008), In vitro, 
different brands of IVIg showed significant differences in the potency in suppression NK cell 
cytolytic activity.  
So far, 9 randomised placebo-controlled trials (RCTs) investigating IVIg in women with 
RPL have been published with conflicting results (The German RSA/IVIG group, 1994; 
Christiansen et al.,1995; Coulam et al., 1995; Perino et al.,1997; Stephenson et al., 1998; 
Jablonowska et al., 1999; Christiansen et al., 2002; Stephenson et al., 2010; Christiansen 
et al., 2015). The last Cochrane systematic review with meta-analysis was updated in 
2014 (Wong et al., 2014) and found overall no significant beneficial effect of IVIg over 
placebo in improving the live birth rate after RPL. However, this review only included one 
outcome (live birth after 20th weeks of gestation) and a single subgroup analysis (trials 
reporting intention to treat), and it did not include the most recent placebo-controlled trials 
of IVIg in RPL (Stephenson et al., 2010, Christiansen et al., 2015). 
In this survey, we review the evidence from our own and other relevant studies for a 
possible treatment effect of IVIg in RPL. The focus will be to identify subsets of women 
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with RPL who will benefit most by IVIg treatment and identify treatment protocols, which 
will be most efficient.   
 
Primary versus secondary RPL. 
A priori, there is some evidence that the immunological disturbances characterizing 
primary and secondary RPL are different. Increased numbers and activity of peripheral 
blood NK cells have been reported in primary RPL compared with secondary RPL 
(Shakhar et al., 2003; Kuon et al., 2017) whereas increased plasma levels of inflammatory 
cytokines and immunity against male-specific minor histocompatilbility (HY) antigens seem 
to characterize secondary RPL (Piosek et al., 2013; Nielsen et al., 2009). Different effects 
of IVIg in the two RPL subsets are therefore expected. The systematic review and meta-
analysis by Hutton et al. (2007) found that the treatment effect of IVIg was significant in 
secondary RPL but not in primary RPL. We therefore found it relevant to perform an 
updated meta-analysis with separate analyses of primary and secondary RPL, 
respectively.  
In the systematic review and meta-analysis (Egerup et al., 2015), 11 relevant RCTs were 
identified involving unexplained RPL patients; nine of them compared IVIg to placebo and 
two RCTs compared IVIg to other treatments. We aimed to retrieve Individual Patient Data 
(IPD) from the original authors to be able to do relevant subgroup analyses with high 
statistical power but were only successful to obtain IPD from 5 of the studies. In all 
included patients, a relative risk (RR) of 0.92 (95% CI 0.75-1.12) for no live birth (and a RR 
of 1.02 [95% CI 0.70-1.48] for live birth in patients that could be classified as either primary 
or secondary RPL in the publications) (Fig. 1) was found after IVIg. In patients with 
secondary RPL, the RR for live birth after IVIg was 1.24 (0.96-1.59 ; p = 0.06), which can 
be translated into a borderline significant benefit of IVIg in secondary RPL (Fig. 1). This p-
value is two-tailed but since the null hypothesis was that IVIg does not improve pregnancy 
success rate in secondary RPL in can be argued whether a one-sided test should be 
applied instead and the p-value would then be 0.03.  
Wang et al. (2016) published a similar systematic review and meta-analysis on the effect 
of IVIg in RPL excluding two RCTs with no placebo group, which were included in the 
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meta-analysis by Egerup et al., but including two Chinese RCTs. The outcome measure 
was live birth. The meta-analysis found that IVIg treatment was associated with a RR for 
birth of 1.26 (95% CI 0.99-1.60; p = 0.06, one-sided test p = 0.03) in secondary RPL 
versus RR = 0.88 (95% CI 0.71-1.08; p = 0.20) in primary RPL (Fig 1). The difference 
between the effect of IVIg in the two subgroups was significantly different (p = 0.02). Both 
meta-analyses thus agree that IVIg has a borderline significant therapeutic effect in 
secondary RPL and this subset of patients must be considered the main target group for 
further RCTs.     
As pointed out, two RCTs (Triolo et al., 2003; Mahmoud et al., 2004) were included in the 
Egerup et al. (2015) meta-analysis but not in the meta-analysis by Wang et al. (2016) 
whereas two RCTs (Liu and Chen, 2010; Lin and Li, 2015) were included in the latter but 
not the former meta-analysis. Since neither of these RCTs provided information separately 
for patients with primary or secondary RPL, combining all primary or secondary RPL 
patients, respectively, from the two meta-analyses is not feasible; such an analysis will 
comprise the same RCTs shown in Fig. 1. However, in Fig. 2 and Fig. 3 we have 
performed an analysis of all patients in the 13 RCTs included in the two meta-analyses. 
Data are shown as extracted from the original publications by Wang et al. (2016). Our own 
data extraction from the same original RCTs provides slightly different results. Two Forest 
plots are shown: in Fig. 2 the RCTs are combined by the random effects method, which is 
the more conservative method in which the group means are a random sample from a 
population. In this analysis, the combined RR for live birth in IVIg-treated versus placebo-
treated patients is 1.17 (95% CI 0.95-1.44; p = 0.14). Performing the analysis using the 
fixed models method (Fig. 3) in which the group means are fixed, it is found that the RR for 
live birth in the IVIg-treated patients is significantly higher than in the placebo-treated 
patients (RR = 1.20; 95% CI 1.06-1.37; p = 0.004). However, since significant 
heterogeneity is found when comparing RRs of the 13 RCTs, the analysis by the random 
effects method has highest validity.     
 
Low versus high dosages of IVIg 
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In the treatment of several autoimmune diseases, IVIg protocols providing 0.4 g/kg body 
weight for 5 consecutive days are standard doses with documented clinical effect (Imbach, 
2004). None of the RCTs of IVIg in RPL has administered dosages approaching these 
doses. In one of the RCTs by Christiansen et al. (2002), 0.8 g/kg body weight each week 
was given; which is the highest dose given in any RCT. In almost all published trials, the 
protocol prescribed 0.4g/kg body weight with 2-3 weeks intervals. In our meta-analysis 
(Egerup et al., 2015) we looked at the efficiency of IVIg in RCTs providing dosages above 
versus below the median dosage of 84 g IVIg until gestational week 10 in all RCTs. The 
RR for no live birth (= miscarriage) in the high dosage group was 0.85 (95% CI 0.64-1.12) 
compared with RR 1.19 (95% CI 0.81-1.75) in the low dosage group, the difference 
between RRs was not significant (p = 0.17). The trend for higher treatment efficiency with 
the higher doses should be explored in future studies. However, in a pilot study from the 
RPL clinic at Copenhagen University Hospital, a substantial increased risk of side effects 
especially severe headache was experienced using a protocol with four weekly infusions 
of IVIg.  
 
Patients with autoantibodies versus no autoantibodies 
IVIg has a documented effect in a series of diseases with an autoimmune background 
such as idiopathic thrombocytopenic purpura, Guillain-Barré syndrome and myasthenia 
gravis often characterized by the presence of autoantibodies. It is therefore natural to 
suggest that it will exhibit higher efficiency in women with RPL positive for autoantibodies 
compared with those without. In a cohort of 52 women with RPL after IVF/ICSI treatment 
who were treated with a combination of IVIg and prednisone (10 mg daily) from the start of 
the next IVF/ICSI cycle (Nyborg et al., 2014), the cumulative live birth rate after up to 5 
IVF/ICSI attempts with immunomodulation was 68.4% in patients positive for at least one 
of the autoantibodies routinely investigated in the RPL Unit at Copenhagen University 
Hospital (IgG anticardiolipin, antithyroid-peroxidase, antinuclear, anti-ds-DNA antibodies 
and lupus anticoagulant) compared with 57.6% in those completely negative for the 
autoantibodies (p = 0.44). Although the difference was not statistically significant, the 11% 
better outcome in the autoantibody-positive patients calls for further studies on 
immunological biomarkers that  can identify a patient group, which benefits from IVIg. In 
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addition to autoantibodies, it would be of particular interest to study whether patients with 
high natural killer (NK) cell count or cytotoxicity in the blood or endometrium constitute a 
target group for IVIg therapy since numerous studies have shown that IVIg treatment of 
women with RPL reduces these NK-cell related parameters (Roussev et al., 2007; Moraru 
et al., 2012) and the reduction of  NKT or NK cell numbers after IVIg may increase the live 
birth rate (van den Heuvel et al,, 2007; Heilmann et al., 2010).  
 
Pre-conception versus post-conception IVIg treatment 
Implementation of some of the effects of IVIg on immunological interactions takes time and 
therefore starting infusions only when the pregnancy test is positive may, in principle, be 
too late to prevent a new pregnancy loss in women with RPL in the early first trimester. 
Hutton et al. (2007) in their meta-analysis did several sensitivity analyses and found that in 
RCTs of IVIg in RPL where infusions were started before conception, the outcome in the 
treated patients was significantly better than in those who received placebo whereas no 
treatment effect could be found in RCTs starting infusions after conception (Fig. 4). In the 
meta-analysis by Wang et al. (2016) including a higher number of RCTs similar findings 
were reported (Fig. 4). The RR for live birth in patients who received  IVIg before 
conception versus those who received  placebo was 1.69 (95% CI 1.33-2.14; p < 0.0001). 
However, it should be noticed that there was substantial overlap between the RCTs 
analyzed by Hutton et al. (2007) and Wang et al. (2016).  
These results are in line with follow-up data from our latest double-blind RCT on IVIg in 
patients with secondary RPL (Christiansen et al., 2015). In this RCT, an only 5% higher 
live birth rate was found in IVIg-treated women with secondary RPL compared with those 
who received placebo. However, all patients who miscarried in the trial were offered active 
treatment with IVIg in their next pregnancy. Since the allocation code was not broken 
before 2014, the treatment in the next pregnancy was in almost all cases given without 
knowledge of previous treatment. Figure 5 shows outcome in the first IVIg-treated 
pregnancy after participation in the RCT according to the treatment received in the RCT. 
The patients received the first IVIg infusion in the subsequent pregnancy median 25 weeks 
(range 10-51 weeks) after the first IVIg infusion or median 28 weeks (range 17-121 weeks) 
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after the first placebo infusion in the RCT. The mean number of previous pregnancy losses 
and age were comparable between the two groups (Fig. 5). The live birth rate was 
significantly higher (RR = 9.60, 95% CI 1.44-63.77, p < 0.02) in those who had previously 
miscarried in spite of IVIg treatment compared with those who miscarried with placebo. 
The results concur with the data in Figure 4: treatment with IVIg prior to conception 
increases the chance of live birth. The difference between the RCTs in Figure 4 that 
provided  IVIg before conception and our follow-up study is, that in the former trials IVIg 
was provided  to non-pregnant patients typically few weeks or months prior to conception 
whereas in our follow-up study all patients had secondary RPL with a very high number of 
previous losses and they were pregnant at the time of the first IVIg infusion(s). In normal 
pregnancies fetal tissue is often recognized by the maternal T-  and B-cells resulting in 
formation of IgG antibodies against fetal HLA or long-lasting cellular immunity against 
male-specific HY minor antigens (Verdijk et al., 2004). In normal pregnancies trophoblast 
is resistant to damage by activated T-effector cells or NK-cells but bystander damage by 
excessive immune inflammation in the decidua may render the trophoblast susceptible to 
damage by T- and NK cells, which may result in pregnancy loss and RPL (Mellor and 
Munn, 2006) The role of IVIg in prevention of RPL may be to reduce this decidual 
inflammation.    
 Decidual inflammation may be partially regulated by T-regulatory cells (T-regs) in the 
decidual tissue and uterine lymph nodes. This recruitment of T-regs may be promoted by 
estrogen and seminal antigens in the uterus already at the time of conception (Robertson 
et al., 2018) but further selection and commitment of T-regs probably take place after 
implantation. The T-reg response is enhanced by the presence of dendritic cell, which 
promote a T-reg response. The CD200 check point inhibitor (present in IVIg) seems in 
murine studies to activate dendritic cells, which may enhance the T-reg response when 
given before pregnancy and reduce pregnancy loss rate (Gorczynski et al., 2002). Other 
mechanisms of induction of T-regs by IVIg have been reported (Trinath et al., 2013) 
The seemingly higher therapeutic effect of IVIg in our follow-up study compared with the 
RCTs where IVIg was initiated prior to conception (RR for live birth 9.60 vs 1.67-2.39; Fig 
5, Hutton et al., 2007; Wang et al., 2016) may from an immunological point of view be 
explained by hypothesizing that T-regs reducing inflammation in the decidua are being 
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positively selected in uterine lymph nodes in the presence of high IVIg concentrations 
(Trinath et al., 2013). Relevant immunological investigations in women with RPL before 
and after IVIg treatment are needed to clarify this issue, however, the most important 
investigations of immune competent cells in the uterine lymph nodes and endometrium 
pose severe methodological challenges.  
 
Conclusion 
In meta-analyses of all RCTs performing no sensitivity analyses, the therapeutic benefit of 
IVIg in the prevention of RPL is non-significant. Our subgroup analyses suggested that 
women with secondary RPL may potentially be more responsive to IVIg when compared to 
women with primary RPL. Furthermore, initiating IVIg before conception seems to increase 
the live birth rate whereas no or only weak effects can be found in RCTs starting infusions 
during pregnancy. IVIg dosages closer to those used in autoimmune/inflammatory 
diseases might be more efficient than lower dosages and the treatment might be more 
efficient in patients positive for biomarkers associated with dysregulated immunity than in 
those without. In the planning of future RCTs investigating the efficiency of IVIg in RPL 
treatment, the lessons learned in the trials undertaken so far should be incorporated. In 
short, in future trials on the topic, both more methodological and biological rigor (selection 
according to relevant biomarkers) must be present.  
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Legends to figures 
 
Figure 1:  Forest plots depicting results from two meta-analyses of the efficiency of 
intravenous immunoglobulin (IVIg) in patients with primary and secondary recurrent 
pregnancy loss (RPL), respectively.  In both studies , the outcome measure is live 
birth.  The difference between the outcome measure in the two subgroups was 
statistically significant both in the Wang et al. study (p = 0.02) and in the Egerup et 
al. study (p = 0.03). 
 
Figure 2: Forest plot showing the combined relative risk (RR) for live birth in all 
patients with recurrent pregnancy loss (RPL) who participated in randomized 
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controlled trials of intravenous immunoglobulin (IVIg) versus placebo or other 
treatment. Data were combined by the random effects method. 
 
Figure 3: Forest plot showing the combined relative risk (RR) for live birth in all 
patients with recurrent pregnancy loss (RPL) who participated in randomized 
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controlled trials of intravenous immunoglobulin (IVIg) versus placebo or other 
treatment. Data were combined by the fixed effects method. 
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Figure 4: Forest plots from two meta-analyses of the efficiency of intravenous 
immunoglobulin (IVIg) in patients with recurrent pregnancy loss (RPL) who 
participated in randomized controlled trials where infusions were initiated before or 
after conception, respectively. In both meta-analyses the outcome measure was live 
birth. The differences between the outcome measure in the two subsets were 
statistically significant in the Wang et al. (2016) study (p = 0.005). 
 
Figure 5:  Outcome of the first pregnancies with infusions of intravenous 
immunoglobulin (IVIg) subsequent to a pregnancy loss happening when the patients 
participated in a placebo-controlled trial of IVIg in secondary recurrent pregnancy 
loss (RPL). AC
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